Condition
Transarterial Chemoembolization clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Transarterial Chemoembolization clinical trials that are recruiting, at sites in 2 countries (most in China (4), United States (1)). By phase: Phase 3 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 2Countries
Newest Transarterial Chemoembolization clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Adjuvant TACE after curative liver cancer surgery for patients with high-risk recurrence features | Phase 3 | Nanning | Recruiting | Feb 18, 2026 |
| Drug-eluting bead transarterial chemoembolization for large recurrent or refractory DLBCL masses | — | Fuzhou, Fujian | Recruiting | Sep 30, 2025 |
| Measuring blood flow during liver embolization procedures | — | Madison, Wisconsin | Recruiting | May 14, 2025 |
| Collecting data on treatment effectiveness and safety for patients with advanced liver cancer | — | Guangzhou, Guangdong | Recruiting | Jan 23, 2025 |
| Combining TACE with Camrelizumab and Apatinib for Liver Cancer | Phase 3 | Chengdu, Sichuan | Recruiting | Jul 3, 2024 |
All recruiting trials (5)
-
Adjuvant TACE after curative liver cancer surgery for patients with high-risk recurrence features
This trial will see if giving TACE after curative liver surgery lowers the chance the cancer comes back in people who have high-risk features for recurrence.
-
Drug-eluting bead transarterial chemoembolization for large recurrent or refractory DLBCL masses
This retrospective study will try drug-eluting bead transarterial chemoembolization (DEB-TACE) to shrink and control large recurrent or refractory DLBCL masses in adults.
-
Measuring blood flow during liver embolization procedures
This study is testing a new method to measure blood flow in patients getting liver embolization to see if it helps make treatments for liver tumors more effective.
-
Collecting data on treatment effectiveness and safety for patients with advanced liver cancer
This study is testing how well a combination of a specific cancer treatment and immunotherapy works for patients with advanced liver cancer who haven't been treated before or have had their cancer come back.
-
Combining TACE with Camrelizumab and Apatinib for Liver Cancer
This study is testing if combining a liver cancer treatment called TACE with two drugs, camrelizumab and apatinib, can help people with advanced liver cancer live longer and feel better compared to standard treatments.
Related topics
Quick answers
How many Transarterial Chemoembolization clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in China (4 trials), United States (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.